BIOMET, INC. for BIOMET, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
P.L. 111-148, Patient Protection and Affordable Care Act, provisions related to accountable care organizations and gainsharing; Tax policy; FDA 510(k) reform; Medicare Payment Policy including Outpatient Prospective Payment Ruling and the Inpatient Prospective Payment ruling for FY2010.
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM C KOLTER | — |
Medical/Disease Research/Clinical Labs MED
S.3398 Medical Device Safety Act of 2008- all provisions related to federal pre-emption of state laws with respect to Call III devices; S.3408 Comparative Effectiveness Research Act of 2008- all provisions related to establishment of a Health care Comparative Research Institute; and FDA Globalization Act - provisions related to inspection fees and schedules. S. 3408: Comparative Effectiveness Research Act of 2008 - All provisions related to establishment of a Health Care Comparative Research Institute; FDA Globalization Act (draft legislation in House and Senateno bill number yet) - Provisions related to inspection fees and schedules
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILLIAM C KOLTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.